Elsevier

Brain Research Bulletin

Volume 54, Issue 5, 15 March 2001, Pages 565-568
Brain Research Bulletin

Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer’s disease

https://doi.org/10.1016/S0361-9230(01)00450-6Get rights and content

Abstract

Free radical-induced oxidative damage may be involved in the neurodegenerative process associated with Alzheimer’s disease (AD). 8-Isoprostaglandin F (iPF-III) is an isoprostane derived from free radical-induced non-enzymatic oxidation of arachidonic acid. It is formed in vivo and is an indicator of lipid peroxidation. Measurements were made of iPF-III in the urine of patients with mild to moderate dementia associated with probable AD and compared to those in the urine of non-demented subjects, who were similar in age and gender. 2,3-Dinor thromboxane B2 (dinor TXB2), a urinary metabolite of TXB2 was also measured, and served as an indicator of the enzymatic transformation of a product of arachidonic acid. Enzyme linked immunoassays were used to measure iPF-III and dinor TXB2 in the urine. The concentration of iPF-III was significantly elevated in urine of patients assessed to have mild to moderate dementia as compared to non-demented patients. The concentration of urinary dinor TXB2 was also significantly elevated in the patients with dementia and probable AD as compared to the non-demented subjects. There was considerable overlap of values obtained for demented and non-demented patients for iPF-III and dinor TXB2, respectively. The observed elevation of iPF-III suggests that patients with mild to moderate dementia associated with probable AD are experiencing significant oxidative stress. This finding is consistent with current data suggesting that oxidative stress may be occurring in patients with dementia and probable AD. The increase of dinor TXB2 may indicate that enzymatic processes related to the metabolism of arachidonic acid-derived products are also increased in demented patients with probable AD.

Introduction

It is estimated that at least 4 million people in the United States have been diagnosed with Alzheimer’s disease (AD) and that up to 50% of people over the age of 85 have AD [2]. There is extensive evidence indicating that oxidative stress, resulting in the destruction and death of neurons in the brain, is a contributing factor to the development and expression of AD [9].

Assessment of free radical-induced oxidative stress in the brains of patients with AD has revealed an increase in thiobarbituric acid-reactive substances in the hippocampus [6] and the temporal cortex 8, 11, indicative of significant lipid peroxidation. The aldehyde product of lipid peroxidation, 4-hydroxynonenal, is significantly increased in the amygdala, the hippocampus, and the parahippocampal gyrus of the AD brain and coincides in these areas with histopathology characteristic of AD [10]. Elevated levels of 4-hydroxynonenal are also found in the cerebrospinal fluid of patients with probable AD [7]. Oxidative degradation of protein is detected in the inferior parietal lobe and hippocampus of brains from patients diagnosed with AD [5] as is increased nitration of proteins and the presence of peroxynitrite 5, 22. A significant increase in oxidative damage to mitochondrial [12] and nuclear [4] DNA in brains of patients with AD is also observed. These findings strongly support the suggestion that the brains of patients with Alzheimer’s disease are in a state of oxidative stress.

F2-isoprostanes are formed by the non-enzymatic peroxidation of arachidonic acid in phospholipids and polyunsaturated fatty acids, by free radicals 15, 20. The F2-isoprostane, 8-isoprostaglandin F (iPF-III), has been quantified in human tissue, plasma, and urine, and is viewed as a reliable indicator of oxidative stress occurring in vivo 20, 21. In a study conducted post-mortem, a significant increase in iPF-III is found in the frontal and temporal poles of the brains of patients with AD as compared to brains of patients who were not reported to be demented prior to death and were without significant histological signs of AD upon autopsy [19]. A significant increase in iPF-III is also observed post-mortem, in the ventricular fluid of patients diagnosed with AD [14]. The direct measurement of a product of lipid peroxidation in the brain tissue and ventricular fluid of patients with AD provides important evidence of the occurrence of oxidative stress in the brain of AD patients.

In the present study, the hypothesis was tested that patients with dementia and probable AD are undergoing significant oxidative stress. This hypothesis was tested by comparing the concentration of iPF-III, a product of free radical-induced lipid peroxidation, in the urine of patients with mild to moderate dementia and a diagnosis of probable AD, with the concentration of iPF-III in the urine of non-demented control subjects, similar in age. Also compared between demented and non-demented subjects was the concentration of 2,3-dinor thromboxane B2 (dinor TXB2), a metabolite of TXB2, which is also detectable in the urine [23]. TXB2 is synthesized from arachidonic acid by an enzymatic process involving cyclooxygenase [21]. Measurements of dinor TXB2 allowed for a comparison of enzymatic metabolic activity with the non-enzymatic autoxidation associated with the generation of iPF-III by free radicals. The use of urine provided a non-invasive procedure for assessing the possibility that patients with dementia and probable AD were experiencing significant oxidative stress resulting in increased excretion of a biomarker indicative of this stress.

Section snippets

Subjects

Participants in the study (non-demented and demented) were over the age of 65, were ambulatory, and were living in the community or residing in a nursing home. Participants were receiving medical care from physicians at the Center for Aging of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine. The diagnosis of dementia and probable AD was made according to NINDS/ADRDA criteria and evaluation of the patient by a geriatrician and a neurologist or geriatric

Results

A total of 71 patients were enrolled in the study. There were 33 control subjects and 38 subjects diagnosed with mild to moderate dementia. The mean age of the subjects in each group was similar, as was the relative distribution of female and male patients. Information on serum cholesterol and triglyceride levels, the use of non-steroidal anti-inflammatory drugs (NSAIDs), vitamin E, and alcohol were obtained, as were data on the occurrence of chronic obstructive pulmonary disease (COPD) and

Discussion

The present study demonstrated that the concentration of iPF-III measured in the urine of patients with mild to moderate dementia associated with probable AD, was significantly elevated as compared to non-demented control patients. Urinary levels of dinor TXB2 were also significantly increased in patients diagnosed with mild to moderate dementia associated with probable AD as compared to control subjects who were not demented.

Measurements made post-mortem reveal significant elevations of F2

Acknowledgements

The authors would like to acknowledge the assistance of Dr. T. P. Stein, for the use of his laboratory to perform certain procedures involved in this study. The assistance of Dr. Sherry Carol-Pomerantz in the statistical analysis of the data and Ms. Lisa Giffen for her help in collecting data from patient records, are also gratefully acknowledged. This work was supported in part, by a grant from the American Osteopathic Association (F99-2) to Dr. Tuppo.

References (24)

  • O Vesterqvist et al.

    Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions

    Prostaglandins

    (1984)
  • C Behl

    Alzheimer’s disease and oxidative stressImplications for novel therapeutic approaches

    Prog. Neurobiol.

    (1998)
  • Cited by (75)

    • Analysis of eicosanoid oxidation products in Alzheimer brain by LC-MS with uniformly 13C-labeled internal standards

      2018, Free Radical Biology and Medicine
      Citation Excerpt :

      It is common to assay one compound or class of compounds as representative of overall oxidative stress. For example, numerous studies of F2 isoprostanes (iPs) have been performed on material from people with AD and pre-AD syndromes [8–19]. There is some consensus that F2-iP concentrations are increased in the CSF of persons with AD, however, the results from brain tissue, plasma, and urine are less clear.

    • Unregulated Lipid Peroxidation in Neurological Dysfunction

      2014, Omega-3 Fatty Acids in Brain and Neurological Health
    View all citing articles on Scopus

    Present address: Western University of Health Sciences, College of Osteopathic Medicine, 302 Second Street, Pomona, CA 91766, USA.

    View full text